Lifileucel Market Summary

Key Factors Driving Lifileucel Growth

1. Rapid commercial uptake in advanced melanoma: Lifileucel, marketed as AMTAGVI, is the first FDA-approved tumor-derived autologous T-cell therapy and is indicated for adults with unresectable or metastatic melanoma previously treated with a PD-1 inhibitor and, when applicable, BRAF/MEK-targeted therapy. Iovance reported $220 million in US AMTAGVI revenue in 2025, its first full calendar year of launch, contributing to total company revenue of approximately $264 million. This represented a substantial increase from the early launch period and demonstrates accelerating physician and patient adoption.

2. Durable responses in heavily pretreated patients support clinical differentiation: The pivotal C-144-01 study demonstrated an ORR of 31.5% in the FDA-approved dose population, including complete responses in 4.1% of patients. More importantly, the five-year analysis showed a median duration of response of 36.5 months, while 19.7% of patients were alive at five years. In a population with advanced melanoma that has progressed after checkpoint inhibitors and targeted therapy, the durability of responses is an important differentiating factor for AMTAGVI.

3. Real-world evidence is encouraging earlier use and referrals: Iovance has reported real-world data showing an approximately 44% physician-assessed ORR, with response rates reaching approximately 52% among patients treated in third line or earlier, compared with ~33% after three or more prior lines. These findings are particularly important commercially because they suggest that clinicians may increasingly refer patients for TIL therapy before they become extremely heavily pretreated. Iovance has specifically cited real-world response data as a driver of increasing adoption and referrals toward earlier treatment.

4. Expansion of the authorized treatment-center network is improving access: AMTAGVI requires specialized cell-therapy infrastructure, including tumor resection, manufacturing, lymphodepletion and infusion. Iovance reported that its network had expanded to more than 90 US and Canadian authorized treatment centers (ATCs) by Q1 2026 and expected to activate at least 110 ATCs by the end of 2026. Increasing ATC coverage, including community-based centers, reduces geographic and logistical barriers and is a major determinant of commercial uptake for a personalized cell therapy. Iovance also reports a manufacturing turnaround time of 32 days or less, which can improve accessibility compared with longer manufacturing timelines.

5. Expansion beyond melanoma creates a potentially much larger long-term opportunity: Lifileucel is being developed in several additional solid tumors, providing opportunities to evolve AMTAGVI from a melanoma product into a broader TIL franchise. Particularly important programs include second-line advanced NSCLC, for which lifileucel received FDA Fast Track designation, and the SARATOGA registrational Phase III trial in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Iovance is also evaluating lifileucel in metastatic serous endometrial cancer, where the company reported a 40% objective response rate in an early dataset. These programs remain investigational and should not be considered approved indications, but positive results could substantially expand the commercial opportunity.

Lifileucel Recent Developments

In November 2025, Five-year follow-up data from the Phase II C-144-01 study (NCT02360579) showed that Lifileucel (Amtagvi) maintained efficacy and favorable safety in pretreated patients with advanced melanoma, showcasing the long-term promise of the 1-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy.

“Lifileucel Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Lifileucel for approved indication like Malignant melanoma; as well as potential indication like Adenocarcinoma, Cervical cancer, Colorectal cancer, Endometrial cancer, Non-small cell lung cancer, Osteosarcoma, Ovarian cancer, and Liposarcoma in the 7MM. A detailed picture of Lifileucel’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Lifileucel for approved and potential indications. The Lifileucel market report provides insights about Lifileucel’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Lifileucel performance, future market assessments inclusive of the Lifileucel market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Lifileucel sales forecasts, along with factors driving its market.

Lifileucel Drug Summary

Lifileucel (AMTAGVI) is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy developed by Iovance Biotherapeutics and is the first FDA-approved cellular therapy for a solid tumor. It is manufactured by surgically removing tumor tissue from an individual patient, isolating T cells from the tumor, expanding these tumor-reactive lymphocytes ex vivo into a large population, and then cryopreserving them for reinfusion into the same patient. The therapy is composed primarily of CD4+ and CD8+ T cells and is designed to enhance the patient’s immune-mediated attack against cancer cells. AMTAGVI is administered as a one-time intravenous infusion following a lymphodepleting chemotherapy regimen and is indicated in the U.S. for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, when BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor. The FDA granted accelerated approval in February 2024, based on objective response rate in previously treated advanced melanoma. The report provides Lifileucel’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Lifileucel Market Report

The report provides insights into:

• A comprehensive product overview including the Lifileucel MoA, description, dosage and administration, research and development activities in approved indications like Malignant melanoma; as well as potential indication like Adenocarcinoma, Cervical cancer, Colorectal cancer, Endometrial cancer, Non-small cell lung cancer, Osteosarcoma, Ovarian cancer, and Liposarcoma.
• Elaborated details on Lifileucel regulatory milestones and other development activities have been provided in Lifileucel market report.
• The report also highlights Lifileucel‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Lifileucel market report also covers the patents information, generic entry and impact on cost cut.
• The Lifileucel market report contains current and forecasted Lifileucel sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Lifileucel market report also features the SWOT analysis with analyst views for Lifileucel in approved and potential indications.

Methodology

The Lifileucel market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lifileucel Analytical Perspective by DelveInsight

• In-depth Lifileucel Market Assessment

This Lifileucel sales market forecast report provides a detailed market assessment of Lifileucel for approved indication like Malignant melanoma; as well as potential indication like Adenocarcinoma, Cervical cancer, Colorectal cancer, Endometrial cancer, Non-small cell lung cancer, Osteosarcoma, Ovarian cancer, and Liposarcoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Lifileucel sales data uptil 2034.

• Lifileucel Clinical Assessment

The Lifileucel market report provides the clinical trials information of Lifileucel for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Lifileucel Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Lifileucel Market Potential & Revenue Forecast

• Projected market size for the Lifileucel and its key indications
• Estimated Lifileucel sales potential (Lifileucel peak sales forecasts)
• Lifileucel Pricing strategies and reimbursement landscape

Lifileucel Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Lifileucel Market positioning compared to existing treatments
• Lifileucel Strengths & weaknesses relative to competitors

Lifileucel Regulatory & Commercial Milestones

• Lifileucel Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Lifileucel Clinical Differentiation

• Lifileucel Efficacy & safety advantages over existing drugs
• Lifileucel Unique selling points

Lifileucel Market Report Highlights

• In the coming years, the Lifileucel market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Lifileucel companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lifileucel’s dominance.
• Other emerging products for Malignant melanoma; as well as potential indication like Adenocarcinoma, Cervical cancer, Colorectal cancer, Endometrial cancer, Non-small cell lung cancer, Osteosarcoma, Ovarian cancer, and Liposarcoma are expected to give tough market competition to Lifileucel and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lifileucel in approved and potential indications.
• Analyse Lifileucel cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Lifileucel sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Lifileucel in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Lifileucel? How strong is Lifileucel’s clinical and commercial performance?
• What is Lifileucel’s clinical trial status in each individual indications such as Malignant melanoma; as well as potential indication like Adenocarcinoma, Cervical cancer, Colorectal cancer, Endometrial cancer, Non-small cell lung cancer, Osteosarcoma, Ovarian cancer, and Liposarcoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lifileucel Manufacturers?
• What are the key designations that have been granted to Lifileucel for approved and potential indications? How are they going to impact Lifileucel’s penetration in various geographies?
• What is the current and forecasted Lifileucel market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Lifileucel in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Lifileucel for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Lifileucel? What is the duration of therapy and what are the geographical variations in cost per patient?